CALC stock forecast, quote, news & analysis
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage... Show more
Why CalciMedica (CALC) Stock Is Down 27% in the Last 30 Days
Key Takeaways
- CalciMedica (CALC) shares fell roughly 27% over the trailing 30 days, sliding from about $2.32 to near $1.70.
- The decline extended a prolonged multi-month downtrend and followed a 1-for-5 reverse stock split completed in late August.
- Losses came despite a Buy initiation from Guggenheim and FDA alignment on the Phase 2b Auxora trial design, underscoring lingering financing and dilution concerns.
- As a pre-revenue, clinical-stage biotechnology company, CALC remains highly sensitive to cash runway, clinical milestones, and broader risk appetite.
CalciMedica (CALC) Company Overview and Market Position
CalciMedica, Inc. is a clinical-stage biopharmaceutical company headquartered in La Jolla, California. The company develops therapies built around calcium release-activated calcium (CRAC) channel inhibition, a mechanism designed to modulate immune response and protect against tissue cell injury in serious inflammatory and immunologic conditions. Its lead candidate, Auxora (active compound zegocractin, formerly CM4620), is being studied in acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury. The company is also advancing CM5480, an oral CRAC-channel inhibitor, as a potential treatment for pulmonary arterial hypertension (PAH).
CalciMedica has no approved products and generates no product revenue, which places it firmly among early-stage, development-driven biotech names. With a small market capitalization and a focused clinical pipeline, the stock is followed primarily by investors tracking data catalysts, regulatory milestones, and the company's ability to fund its programs.
CalciMedica (CALC) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, CALC declined approximately 27%, moving from a closing level near $2.32 to about $1.70. The move was characterized by steady downward pressure rather than a single sharp event, with the shares setting progressively lower levels through September.
The quarterly trend is even more pronounced. On a split-adjusted basis, the stock traded near $4.90 in late June before sliding to roughly $1.70 by late September — a decline of roughly 65% over the period. This multi-month downtrend reflects persistent selling in the shares alongside the company's limited cash-generating capacity as a pre-revenue developer.
What Drove CALC Stock Price in the Last 30 Days
Several factors contributed to the recent decline. The company completed a 1-for-5 reverse stock split in late August, a step listed companies often take to raise their per-share price and address exchange listing standards. Following the split, the shares continued to trade lower, indicating that the corporate action did not reverse the underlying selling pressure.
Fundamentals also remained a headwind. CalciMedica reported no product revenue and posted a net loss, consistent with its clinical-stage status, while carrying a modest cash balance relative to its development needs. These conditions can keep dilution concerns and financing overhang at the forefront of investor sentiment.
Notably, the decline occurred alongside constructive developments. Guggenheim initiated coverage with a Buy rating, citing the potential of CM5480, and the company announced alignment with the U.S. Food and Drug Administration on endpoints and patient population for its Phase 2b Auxora trial. That the stock still fell despite these updates highlights the weight of broader risk-off sentiment toward speculative, pre-revenue micro-cap biotechs and thin trading conditions.
What Drove CALC Stock Performance Over the Last Quarter
The quarterly decline reflects a broader narrative of a clinical-stage company contending with both execution and capital-market realities. The company reported its second-quarter 2026 results in August with ongoing operating losses typical of its stage. The reverse stock split introduced additional technical and psychological pressure, as post-split shares in underperforming small caps frequently continue to drift lower.
More broadly, small- and micro-cap biotechnology names have faced a challenging environment, with investors demanding clearer paths to clinical data and financing stability. For CalciMedica, the absence of near-term revenue and the dependence on future capital raises kept the shares in a sustained downtrend despite select positive pipeline news.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that are actively trading across the market. While Tickeron offers hundreds of AI trading bots covering thousands of tickers, only the top-performing and most relevant bots are featured in this section. These bots vary in strategy, timeframe, and performance metrics, giving traders a range of data-driven approaches to evaluate. For investors monitoring volatile names such as CALC, these tools can provide an additional, quantitative perspective on market activity. Explore the Trending AI Robots page to review the currently featured bots and their performance.
CALC Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors are likely to focus on the company's clinical execution and balance-sheet durability. Key areas to monitor include enrollment and data updates from the CARPO Phase 2b trial in acute pancreatitis, the investigator-initiated CRSPA study in pediatric asparaginase-induced pancreatic toxicity, and progress on CM5480 in pulmonary arterial hypertension. The company has indicated that an update on the CRSPA program is expected during 2026.
Financing remains a central consideration, as CalciMedica's cash position relative to its development timeline could necessitate additional capital raises. Upcoming quarterly results, expected around November 2026, and any changes in analyst coverage will also shape sentiment. As with all clinical-stage biotechs, outcomes remain inherently uncertain, and investors should weigh both pipeline opportunity and liquidity risk.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CALC's RSI Oscillator ascends from oversold territory
The RSI Indicator for CALC moved out of oversold territory on October 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 31 of the 34 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 66 cases where CALC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on CALC as a result. In 64 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
Following a +16.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where CALC advanced for three days, in 185 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CALC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
CALC broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CALC entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.684) is normal, around the industry mean (3.498). P/E Ratio (-0.199) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. CALC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CALC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology